Premium
Distribution of autoantibodies against the second extracellular loop of α1‐adrenoceptor in patients with primary hypertension
Author(s) -
He Zhongmei,
Wang Xiaoliang,
Yan Zi,
Wu Ye,
Zhao Rongrui,
Ma Xin L,
Liu Huirong
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.5.a1182-c
Subject(s) - autoantibody , medicine , pathogenesis , valvular heart disease , cardiology , cardiomyopathy , dilated cardiomyopathy , hypertensive heart disease , heart disease , titer , disease , essential hypertension , antibody , heart failure , immunology , blood pressure
To observe the distribution of the autoantibodies against the second extracellular loop of human α1AR in the sera of patients with primary hypertension, coronary atherosclerotic heart disease, rheumatic valvular heart disease and dilated cardiomyopathy, the anti‐α1AR‐autoantibodies were detected by SA‐ELISA. The positive rate of the autoantibodies against α1AR in the sera of patients with primary hypertension was obviously higher than those of coronary atherosclerotic heart disease, rheumatic valvular heart disease, dilated cardiomyopathy and healthy subjects (48.8% n=86 vs.30.9% n=68, 23.1% n=30, 20.2% n=39, 9.0% n=100, respectively, p<0.05); The geometric mean titers of the anti‐α1AR‐autoantibodies in patients with primary hypertension was (1:93.5±2.4), which was also substantially higher than other cardiovascular diseases and healthy subjects [(1:53.2±2.6), (1:36.3±1.8), (1:33.8±2.7), (1:16.6±3.8), respectively, p<0.05]. Our results demonstrated for the first time that it is possible that the anti‐α1AR‐autoantibodies in the patients with primary hypertension is related with the pathogenesis of hypertension, and may contribute to a new therapeutic clue for the primary hypertension.